Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 70 years of age.~* Hospitalization for NSTEMI or UA \< 72 hours~Exclusion Criteria:~* Contraindication to P2Y12 inhibitors i.e. clopidogrel, prasugrel or ticagrelor:~* Unable or unwilling to give informed consent or have a life expectancy of less than one year.~* Having received thrombolytic therapy within the previous 24 hours.~* Severe renal function impairment needing dialysis.~* Confirmed or persistent severe hypertension (Systolic Blood Pressure (SBP) \> 180 mmHg and/or Diastolic Blood Pressure (DBP) \>110 mmHg) at randomization.~* At increased bleeding risk, at the investigator's opinion, e.g. because of malignancy.~* Cardiogenic shock (SBP ≤ 80mmHg for \>30 mins) or Intra-Aortic Balloon Pump (IABP) at the time of screening.~* History of major surgery, severe trauma, fracture or organ biopsy within 90 days prior to randomisation.~* Clinically significant out of range values for platelet count or haemoglobin at screening, in the investigator's opinion.~* ACS under dual antiplatelet therapy, e.g. aspirin with a P2Y12 inhibitor; clopidogrel, prasugrel, ticagrelor.~* Patients with a known CYP2C19 genotype at the time of randomization.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Clopidogrel
- Control (Type: ACTIVE_COMPARATOR): Ticagrelor/Prasugrel

Based on this trial design, predict the completion outcome and termination type (if applicable).